Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126838491 | 12683849 | 1 | I | 20160822 | 20160825 | 20160825 | EXP | ES-ROCHE-1819510 | ROCHE | VILLACORTA J, MARITNEZ M, CANO A, CAZAR R, MENDEZ A, GUERRERO M AND JUAREZ G. INCIDENCE AND PROGNOSIS OF BEVACIZUMAB INDUCED RENAL DAMAGE; A TWO YEARS STUDY FROM A SINGLE CENTER (ABSTRACT: FP139). NEPHROLOGY DIALYSIS TRANSPLANTATION 2015;30 (SUPP3):-. | 0.00 | Y | 0.00000 | 20160825 | OT | ES | ES |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126838491 | 12683849 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Unknown | Y | 125085 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126838491 | 12683849 | 1 | Neoplasm malignant |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126838491 | 12683849 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126838491 | 12683849 | Hypertension | |
| 126838491 | 12683849 | Proteinuria | |
| 126838491 | 12683849 | Renal injury |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |